X4 Pharmaceuticals (XFOR) Metrics: History & Chart

X4 Pharmaceuticals, Inc.(XFOR)

Biotechnology · Boston, MA

$2.78-0.12 (-4.26%)

Delayed quote: Oct 6, 2026, 3:00 PM EDT

About X4 Pharmaceuticals, Inc.

X4 Pharmaceuticals, Inc. is a biopharmaceutical firm committed to the discovery, development, and commercialization of innovative therapies for uncommon immune system disorders. Its primary drug candidate, XOLREMDI (also known as mavorixafor), is an orally administered, small-molecule antagonist specifically designed to target the chemokine receptor CXCR4. This compound is currently undergoing Phase 3 clinical trials for the management of WHIM syndrome, a rare immunodeficiency characterized by symptoms such as warts, hypogammaglobulinemia, recurrent infections, and myelokathexis. To broaden its global presence, the company has entered into several licensing agreements: A partnership with Abbisko Therapeutics Co Ltd. grants rights for the manufacturing and distribution of XOLREMDI in mainland China, Taiwan, Hong Kong, and Macau. Another agreement with Norgine covers the development, production, and commercialization of mavorixafor across Europe, Australia, and New Zealand. Furthermore, X4 Pharmaceuticals holds a comprehensive agreement with Genzyme Corporation concerning the CXCR4 receptor, allowing for the development and commercialization of licensed compounds for all medical applications, including therapeutic, preventive, and diagnostic uses. The company maintains its corporate headquarters in Boston, Massachusetts.

Boston, MA

45 employees

www.x4pharma.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Adam R. Craig

View full financials

Third-Party DCF Estimate (FMP)	$19.21
Price Gap vs Third-Party Estimate	+597.44%

7D Total Return	-3.97%
30D Total Return	-28.22%
YTD Total Return	-27.50%
1Y Total Return	-16.67%
3Y Total Return	-89.75%
5Y Total Return	-98.17%
10Y Total Return	N/A
15Y Total Return	N/A
20Y Total Return	N/A

2026	-27.50%
2025	-81.83%
2024	-12.52%
2023	-15.54%
2022	-56.64%
2021	-64.39%
2020

CAGR TTM	-16.59%
CAGR 3Y	-53.19%
CAGR 5Y	-55.06%
CAGR 10Y	N/A
CAGR 15Y	N/A
CAGR 20Y	N/A

PE Ratio	0.70
PE Ratio Avg TTM	4.20
PE Ratio Avg 3Y	4.20
Current VS TTM Avg	-83.34%
Current VS 3Y Avg	-83.34%
Current VS 5Y Avg	-83.34%

All Metrics

XFOR Valuation Metrics

XFOR Stock Price Metrics

XFOR Dividend Metrics

XFOR Growth Rate Metrics

XFOR Discounted Cash Flow Metrics

XFOR Returns By Period

XFOR Yearly Returns

XFOR Average Annual Returns By Period (CAGR)

XFOR Revenue Metrics

XFOR PE Ratio Metrics

XFOR PS Ratio Metrics

XFOR PB Ratio Metrics

XFOR Price to Free Cash Flow Ratio Metrics

XFOR Debt to Equity Ratio Metrics

XFOR PEG Ratio Metrics

XFOR FCF Yield

XFOR Earnings Yield

XFOR EBITDA Yield

XFOR OCF Yield

XFOR EV/EBIT Ratio Metrics

XFOR EV/EBITDA Ratio Metrics

XFOR EV/Assets Ratio Metrics

XFOR EV/Sales Ratio Metrics

XFOR Current Ratio Metrics

XFOR Quick Ratio Metrics

XFOR ROIC Metrics

XFOR Return on Assets Metrics

XFOR Return on Equity Metrics

XFOR Net Profit Margin Metrics

XFOR Gross Profit Margin Metrics

XFOR Tax Rate Metrics

PS Ratio	23.12
PS Ratio Avg TTM	22.58
PS Ratio Avg 3Y	29.60
Current VS TTM Avg	+2.38%
Current VS 3Y Avg	-21.89%
Current VS 5Y Avg	-21.89%

PB Ratio	2.36
PB Ratio Avg TTM	2.78
PB Ratio Avg 3Y	2.25
Current VS TTM Avg	-14.99%
Current VS 3Y Avg	+5.07%
Current VS 5Y Avg	+15.85%

PFCF Ratio	N/A
PFCF Ratio Avg TTM	N/A
PFCF Ratio Avg 3Y	N/A
Current VS TTM Avg	N/A
Current VS 3Y Avg	N/A
Current VS 5Y Avg	N/A

Debt/Equity Ratio	0.50
Debt/Equity Ratio Avg TTM	4.45
Debt/Equity Ratio Avg 3Y	1.29
Current VS TTM Avg	-88.85%
Current VS 3Y Avg	-61.63%
Current VS 5Y Avg	-34.38%

PEG Ratio	N/A
PEG Ratio Avg TTM	N/A
PEG Ratio Avg 3Y	N/A
Current VS TTM Avg	N/A
Current VS 3Y Avg	N/A
Current VS 5Y Avg	N/A

FCF Yield	N/A
FCF Yield Avg TTM	N/A
FCF Yield Avg 3Y	N/A
Current VS TTM Avg	N/A
Current VS 3Y Avg	N/A
Current VS 5Y Avg	N/A

Earnings Yield	142.95%
Earnings Yield Avg TTM	55.02%
Earnings Yield Avg 3Y	55.02%
Current VS TTM Avg	+159.83%
Current VS 3Y Avg	+159.83%
Current VS 5Y Avg	+159.83%

EBITDA Yield	N/A
EBITDA Yield Avg TTM	N/A
EBITDA Yield Avg 3Y	N/A
Current VS TTM Avg	N/A
Current VS 3Y Avg	N/A
Current VS 5Y Avg	N/A

OCF Yield	N/A
OCF Yield Avg TTM	N/A
OCF Yield Avg 3Y	N/A
Current VS TTM Avg	N/A
Current VS 3Y Avg	N/A
Current VS 5Y Avg	N/A

Ev/Ebit Ratio	N/A
Ev/Ebit Ratio Avg TTM	N/A
Ev/Ebit Ratio Avg 3Y	N/A
Current VS TTM Avg	N/A
Current VS 3Y Avg	N/A
Current VS 5Y Avg	N/A

Ev/Ebitda Ratio	N/A
Ev/Ebitda Ratio Avg TTM	N/A
Ev/Ebitda Ratio Avg 3Y	N/A
Current VS TTM Avg	N/A
Current VS 3Y Avg	N/A
Current VS 5Y Avg	N/A

Ev/Assets Ratio	0.98
Ev/Assets Ratio Avg TTM	1.14
Ev/Assets Ratio Avg 3Y	0.81
Current VS TTM Avg	-14.22%
Current VS 3Y Avg	+21.64%
Current VS 5Y Avg	+39.40%

Ev/Sales Ratio	15.68
Ev/Sales Ratio Avg TTM	17.11
Ev/Sales Ratio Avg 3Y	27.85
Current VS TTM Avg	-8.38%
Current VS 3Y Avg	-43.71%
Current VS 5Y Avg	-43.71%

Current Ratio	11.30
Current Ratio Avg TTM	8.09
Current Ratio Avg 3Y	5.73
Current VS TTM Avg	+39.62%
Current VS 3Y Avg	+97.30%
Current VS 5Y Avg	+127.52%

Quick Ratio	11.02
Quick Ratio Avg TTM	7.90
Quick Ratio Avg 3Y	6.06
Current VS TTM Avg	+39.43%
Current VS 3Y Avg	+81.86%
Current VS 5Y Avg	+102.62%

ROIC	(37.61%)
ROIC Avg 3Y	(80.59%)
ROIC Avg 5Y	(75.11%)
Current VS 3Y Avg	+53.32%
Current VS 5Y Avg	+49.92%
Current VS 10Y Avg	+45.54%

ROA	(35.62%)
ROA Avg TTM	(12.96%)
ROA Avg 3Y	(17.08%)
Current VS TTM Avg	-174.78%
Current VS 3Y Avg	-108.53%
Current VS 5Y Avg	-94.30%

ROE	(57.98%)
ROE Avg TTM	(78.51%)
ROE Avg 3Y	(89.50%)
Current VS TTM Avg	+26.15%
Current VS 3Y Avg	+35.21%
Current VS 5Y Avg	+51.67%

Net Profit Margin	(568.80%)
Net Profit Margin Avg TTM	(971.30%)
Net Profit Margin Avg 3Y	(693.86%)
Current VS TTM Avg	+41.44%
Current VS 3Y Avg	+18.02%
Current VS 5Y Avg	-110.86%

Gross Profit Margin	81.22%
Gross Pft Margin Avg TTM	79.65%
Gross Pft Margin Avg 3Y	47.92%
Current VS TTM Avg	+1.97%
Current VS 3Y Avg	+69.50%
Current VS 5Y Avg	+173.80%

Tax Rate	10.76%
Tax Rate Avg 3Y	5.39%
Tax Rate Avg 5Y	5.39%
Current VS 3Y Avg	+99.63%
Current VS 5Y Avg	+99.63%
Current VS 10Y Avg	+99.63%